Cognito Therapeutics, a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases, announced today its CEO Brent Vaughan will speak at CODE Conference, in Beverly Hills, CA, September 27-29, 2021 to discuss Cognito’s ground-breaking technology that has shown the promise of slowing or stopping the progression of Alzheimer’s and its potential to fundamentally expand human cognitive performance.

Event details:

Code 2021 is an annual event hosted by Vox, created by Kara Swisher, that brings together the biggest names in tech. The invitation-only conference convenes the biggest names in the business — executive leaders and promising entrepreneurs — for networking and in-depth conversations. Confirmed speakers this year include Elon Musk, Kevin Durant, Marc Benioff, Ariel Emanuel, and Gary Gensler.

About Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005112/en/